Previous 10 | Next 10 |
2023-07-21 14:01:24 ET Summary Jazz Pharmaceuticals' share price has languished in FY'22 with a number of pressures on its Xywav label. The FDA has supported the competing Lumryz label, stating it is clinically superior to Xywav, chiefly due to its once-nightly dosing regimen. ...
Vanda Pharmaceuticals to Announce Second Quarter 2023 Financial Results on July 27, 2023 PR Newswire Conference Call and Webcast to Follow WASHINGTON , July 20, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will...
2023-06-06 08:07:09 ET Summary We put Vanda Pharmaceuticals in the spotlight today as this small biopharma concern just received Orphan Drug status on Friday for one of its pipeline assets. The company's franchise drug has had litigation setbacks. However, Vanda has other assets a...
Vanda Pharmaceuticals Announces Participation in the Jefferies 2023 Global Healthcare Conference PR Newswire WASHINGTON , June 5, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the Jeffe...
2023-06-02 15:15:50 ET Vanda Pharmaceuticals ( NASDAQ: VNDA ) gained after three straight sessions of declines on Friday after announcing that the FDA granted Orphan Drug Designation for its experimental therapy VCA-894A as a treatment for a type of rare nerve disorder called Charco...
Vanda Pharmaceuticals Announces Presentations at SLEEP 2023 PR Newswire WASHINGTON , June 1, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced participation at SLEEP 2023, to be held in Indianapolis, IN from June 3 ...
Vanda Pharmaceuticals Announces Orphan Drug Designation Granted for VCA-894A, a Novel Antisense Oligonucleotide Candidate for the Treatment of Charcot-Marie-Tooth Disease, Type 2S PR Newswire WASHINGTON , June 1, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (V...
Vanda Pharmaceuticals Reports Results from a Phase III study of Tradipitant in Motion Sickness PR Newswire WASHINGTON , May 25, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the results from its Phase III study of tradipit...
Vanda Pharmaceuticals Responds to Ruling in HETLIOZ® ANDA Appeal PR Newswire WASHINGTON , May 10, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today responded to the ruling in its Hetlioz ® Abbreviated New Drug Application ...
Vanda Pharmaceuticals Announces Presentations at DDW 2023 PR Newswire WASHINGTON , May 4, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced participation at Digestive Disease Week (DDW) 2023, to be held in Chicago, IL ...
News, Short Squeeze, Breakout and More Instantly...
Vanda Pharmaceuticals Inc. Company Name:
VNDA Stock Symbol:
NASDAQ Market:
Vanda Pharmaceuticals Inc. Website:
2024-07-17 04:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-11 07:00:07 ET Charles Duncan from Cantor Fitzgerald issued a price target of $11.00 for VNDA on 2024-07-11 06:12:00. The adjusted price target was set to $11.00. At the time of the announcement, VNDA was trading at $5.21. VNDA currently trades -22.96% versus its...
Federal Court Allows Vanda's HETLIOZ® Patent Lawsuit to Proceed against Teva and Apotex PR Newswire WASHINGTON , July 1, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. District Court for the District of ...